IRVINE, CA, and HERSTAL, BELGIUM - November 15, 2016 - 7:00 AM CET - MDxHealth SA (the "Company") (Euronext Brussels: MDXH) announced today, in conformity with Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that further to the capital increases that were completed on November 7, 2016 in relation to the capital raising that was launched on November 2, 2016, and on November 10, 2016 resulting from the exercise of 49,000 outstanding warrants, its share capital has increased from EUR 36,111,083.86 to EUR 39,761,328.75, and its number of issued and outstanding shares has increased from 45,269,633 to 49,845,595 ordinary shares, through the issuance of a total of 4,575,962 new shares.
The Company was informed by the following shareholders that they still hold shares in excess of 10% of the outstanding shares of the Company:
Biovest Comm. VA, the investment company controlled by Mr. Rudi Mariën, has informed the Company that it subscribed for new shares in the capital raise of November 7, 2016, and that it now owns 13.26% of the outstanding shares of MDxHealth.
Valiance Asset Management Ltd has informed the Company that it subscribed for new shares in the capital raise of November 7, 2016, and that it now controls 12.79% of the outstanding shares of MDxHealth.
Alycho NV, the investment vehicle controlled by Mr. Marc Coucke, fell below the minimum statutory threshold of 3% of the outstanding shares of MDxHealth on November, 2016.
As per November, 2016, following the recent capital increases, MDxHealth had $ 32.4 million in cash and cash equivalents.
In addition to the outstanding shares, the total number of outstanding warrants on the date of this press release amounts to 2,165,688 warrants which (if exercised) would entitle their holders to 2,165,688 shares with voting rights.
About MDxHealth MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 info@mdxhealth.com | Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR) Consilium Strategic Communications UK: +44 20 3709 5701 US: +1 917 322 2571 (Rx Communications Group LLC) mdxhealth@consilium-comms.com |
Important information
The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. No representations are made as to the accuracy or fairness of such forward-looking statements and estimates. Furthermore, forward-looking statements and estimates only speak as of the date of the publication of this document. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
Attachments:
